Identification of Enhanced Vaccine Mimotopes for the P15E Murine Cancer Antigen

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Mar 20

PMID 38506662

Authors

Shiqi Zhou

Yiting Song

Yuan Luo

Breandan Quinn

Yang Jiao

Mark D Long

Scott I Abrams

Jonathan F Lovell

Affiliations

Soon will be listed here.

Abstract

Significance: The MHC-I-restricted p15E tumor rejection epitope is expressed in multiple murine cancer lines and is used as a marker of antitumor cellular immunity, but has seen limited success as a vaccine immunogen. An in vivo screening approach based on a positional peptide microlibraries is used to identify enhanced p15E mimotopes bearing amino acid mutations that induce significantly improved functional immunogenicity relative to vaccination with the wild-type epitope.

References

Ye X, Waite J, Dhanik A, Gupta N, Zhong M, Adler C . Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model. Oncoimmunology. 2020; 9(1):1758602. PMC: 7458611. DOI: 10.1080/2162402X.2020.1758602. View

Alicke B, Totpal K, Schartner J, Berkley A, Lehar S, Capietto A . Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge. J Immunother Cancer. 2020; 8(2). PMC: 7368499. DOI: 10.1136/jitc-2020-000532. View

Lovell J, Baik Y, Keun Choi S, Lee C, Lee J, Miura K . Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine. BMC Med. 2022; 20(1):462. PMC: 9708508. DOI: 10.1186/s12916-022-02661-1. View

He X, Zhou S, Quinn B, Jahagirdar D, Ortega J, Long M . An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity. Cancer Immunol Res. 2022; 10(3):314-326. PMC: 8898291. DOI: 10.1158/2326-6066.CIR-21-0332. View

Huang W, Deng B, Seffouh A, Ortega J, Long C, Suresh R . Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment. NPJ Vaccines. 2020; 5(1):23. PMC: 7080793. DOI: 10.1038/s41541-020-0173-x. View

He X, Zhou S, Quinn B, Huang W, Jahagirdar D, Vega M . Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8 T-Cell Responses. Adv Sci (Weinh). 2021; 8(24):e2103023. PMC: 8693074. DOI: 10.1002/advs.202103023. View

Shimizu K, Iyoda T, Okada M, Yamasaki S, Fujii S . Immune suppression and reversal of the suppressive tumor microenvironment. Int Immunol. 2018; 30(10):445-454. DOI: 10.1093/intimm/dxy042. View

Hamid O, Solomon J, Scotland R, Garcia M, Sian S, Ye W . Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res. 2007; 13(1):215-22. DOI: 10.1158/1078-0432.CCR-06-1450. View

De Silva A, Boesteanu A, Song R, Nagy N, Harhaj E, Harding C . Thermolabile H-2Kb molecules expressed by transporter associated with antigen processing-deficient RMA-S cells are occupied by low-affinity peptides. J Immunol. 1999; 163(8):4413-20. View

10.

Jordan K, McMahan R, Kemmler C, Kappler J, Slansky J . Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A. 2010; 107(10):4652-7. PMC: 2842066. DOI: 10.1073/pnas.0914879107. View

11.

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

12.

McCormick A, Corbo T, Wykoff-Clary S, Nguyen L, Smith M, Palmer K . TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. Vaccine. 2006; 24(40-41):6414-23. DOI: 10.1016/j.vaccine.2006.06.003. View

13.

Zhou S, Luo Y, Lovell J . Vaccine approaches for antigen capture by liposomes. Expert Rev Vaccines. 2023; 22(1):1022-1040. PMC: 10872528. DOI: 10.1080/14760584.2023.2274479. View

14.

Rich R, Green W . Apoptosis of epitope-specific antiretroviral cytotoxic T lymphocytes via Fas ligand-Fas interactions. Viral Immunol. 2006; 19(3):424-33. DOI: 10.1089/vim.2006.19.424. View

15.

White H, Roeder D, Green W . An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes. J Virol. 1994; 68(2):897-904. PMC: 236526. DOI: 10.1128/JVI.68.2.897-904.1994. View

16.

McMahan R, McWilliams J, Jordan K, Dow S, Wilson D, Slansky J . Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest. 2006; 116(9):2543-51. PMC: 1551931. DOI: 10.1172/JCI26936. View

17.

He X, Zhou S, Huang W, Seffouh A, Mabrouk M, Thomas Morgan M . A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8 T Cell Epitopes. ACS Nano. 2021; 15(3):4357-4371. PMC: 10184788. DOI: 10.1021/acsnano.0c07680. View

18.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

19.

Slansky J, Rattis F, Boyd L, Fahmy T, Jaffee E, Schneck J . Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity. 2000; 13(4):529-38. DOI: 10.1016/s1074-7613(00)00052-2. View

20.

Huang W, Deng B, Lin C, Carter K, Geng J, Razi A . A malaria vaccine adjuvant based on recombinant antigen binding to liposomes. Nat Nanotechnol. 2018; 13(12):1174-1181. PMC: 6286227. DOI: 10.1038/s41565-018-0271-3. View